After the Food and Drug Administration surprisingly gave a green light to the company’s Copaxone knockoff, shares in Mylan Inc. (NASDAQ: MYL) are surging 19.5% higher today at 11:30 a.m. EDT.
Teva Pharmaceutical (NYSE: TEVA) received bad news today when the FDA unexpectedly approved Mylan’s long-lasting generic alternative to Copaxone 40 mg.
IMAGE SOURCE: GETTY IMAGES.